Market
What will be the next major milestone for Duvakitug by December 31, 2025?
2
Resolution / Starting Odds
Phase 3 trial completion • 25%
Regulatory approval • 25%
Commercial launch • 25%
Partnership or acquisition • 25%
Official announcements from Teva and Sanofi
Story
Teva and Sanofi's Duvakitug Shows Promise in Phase 2b Trial for IBD, Shares Surge
Dec 17, 2024, 03:45 PM
Teva Pharmaceutical Industries and Sanofi have announced positive results from a Phase 2b clinical trial named RELIEVE UCCD for their drug, Duvakitug, which targets ulcerative colitis and Crohn's disease. The trial showed that Duvakitug met its primary endpoints, with 36.2% of ulcerative colitis patients on a low dose and 47.8% on a high dose achieving clinical remission, compared to 20.45% on placebo. For Crohn's disease, 26.1% of patients on a low dose and 47.8% on a high dose achieved an endoscopic response, compared to 13% on placebo. The drug was well tolerated with no safety signals identified. Following these results, Teva's shares surged by nearly 20%, while Sanofi's shares climbed by almost 5%. The companies plan to initiate Phase 3 development pending regulatory discussions.
View original story
Similar markets
Other milestone • 25%
Partnership with healthcare provider • 25%
Phase 2 trial initiation • 25%
Regulatory approval application • 25%
Foundation dissolved • 25%
No significant changes • 25%
New projects announced • 25%
Leadership change • 25%
Collaborations with other brands • 25%
Expansion of existing projects • 25%
New NFT collection • 25%
Other • 25%
Defense Spending • 25%
Healthcare • 25%
Education • 25%
Infrastructure • 25%
Increased autonomy for SDF regions • 25%
International recognition of SDF • 25%
Heightened tensions with Syrian government • 25%
No significant change • 25%
Government efficiency • 25%
Technology integration • 25%
Regulatory changes • 25%
Other focus • 25%
No major milestone announced • 25%
Initiation of Phase 4 trial • 25%
Regulatory approval in Europe • 25%
Launch of a new indication study • 25%
Released • 25%
Deceased • 25%
Still captive • 25%
Unknown • 25%
Integration issues • 25%
Usability concerns • 25%
Cost-related issues • 25%
Other • 25%
Regulatory Reform • 25%
Technology and Innovation • 25%
Other • 25%
Budget Optimization • 25%
